AD-231
/ Yuhan Corp
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 16, 2026
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Addpharma Inc.
New P1 trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
1 to 1
Of
1
Go to page
1